Biblio
Export 2446 results:
Author Title Type [ Year] Filters: First Letter Of Keyword is A [Clear All Filters]
“Playing Russian Roulette with Alzheimer's Disease Patients: Do the Cognitive Benefits of Lecanemab Outweigh the Risk of Edema, Stroke and Encephalitis?”, J Alzheimers Dis, vol. 92, no. 3, pp. 799-801, 2023.
, “PM2.5 and Dementia in a Low Exposure Setting: The Influence of Odor Identification Ability and APOE.”, J Alzheimers Dis, vol. 92, no. 2, pp. 679-689, 2023.
, “PM2.5 and Dementia in a Low Exposure Setting: The Influence of Odor Identification Ability and APOE.”, J Alzheimers Dis, vol. 92, no. 2, pp. 679-689, 2023.
, “PM2.5 and Dementia in a Low Exposure Setting: The Influence of Odor Identification Ability and APOE.”, J Alzheimers Dis, vol. 92, no. 2, pp. 679-689, 2023.
, “Poor Oral Health as a Risk Factor for Dementia in a Swedish Population: A Cohort Study with 40 Years of Follow-Up.”, J Alzheimers Dis, vol. 92, no. 1, pp. 171-181, 2023.
, “Precision Medicine Approach to Alzheimer's Disease: Rationale and Implications.”, J Alzheimers Dis, vol. 96, no. 2, pp. 429-437, 2023.
, “Preventing Neurocognitive Decline in Adults Aging with HIV: Implications for Practice and Research.”, J Alzheimers Dis, vol. 95, no. 3, pp. 753-768, 2023.
, “Preventing Neurocognitive Decline in Adults Aging with HIV: Implications for Practice and Research.”, J Alzheimers Dis, vol. 95, no. 3, pp. 753-768, 2023.
, “Psychopharmacological Medication Use in Frontotemporal Dementia at the Time of Diagnosis: Comparison with Alzheimer's Disease.”, J Alzheimers Dis, vol. 95, no. 2, pp. 677-685, 2023.
, “Re-Addressing Dementia by Network Medicine and Mechanism-Based Molecular Endotypes.”, J Alzheimers Dis, vol. 96, no. 1, pp. 47-56, 2023.
, “Re-Addressing Dementia by Network Medicine and Mechanism-Based Molecular Endotypes.”, J Alzheimers Dis, vol. 96, no. 1, pp. 47-56, 2023.
, “Re-Addressing Dementia by Network Medicine and Mechanism-Based Molecular Endotypes.”, J Alzheimers Dis, vol. 96, no. 1, pp. 47-56, 2023.
, “Re-Addressing Dementia by Network Medicine and Mechanism-Based Molecular Endotypes.”, J Alzheimers Dis, vol. 96, no. 1, pp. 47-56, 2023.
, “Refining Risk for Alzheimer's Disease Among Heterozygous APOEɛ4 Carriers.”, J Alzheimers Dis, vol. 94, no. 2, pp. 483-489, 2023.
, “Refining Risk for Alzheimer's Disease Among Heterozygous APOEɛ4 Carriers.”, J Alzheimers Dis, vol. 94, no. 2, pp. 483-489, 2023.
, “Refining Risk for Alzheimer's Disease Among Heterozygous APOEɛ4 Carriers.”, J Alzheimers Dis, vol. 94, no. 2, pp. 483-489, 2023.
, “Resveratrol Mediated Regulation of Hippocampal Neuroregenerative Plasticity via SIRT1 Pathway in Synergy with Wnt Signaling: Neurotherapeutic Implications to Mitigate Memory Loss in Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. s1, pp. S125-S140, 2023.
, “Resveratrol Mediated Regulation of Hippocampal Neuroregenerative Plasticity via SIRT1 Pathway in Synergy with Wnt Signaling: Neurotherapeutic Implications to Mitigate Memory Loss in Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. s1, pp. S125-S140, 2023.
, “Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study.”, J Alzheimers Dis, vol. 92, no. 2, pp. 653-665, 2023.
, “Serotonin Degeneration and Amyloid-β Deposition in Mild Cognitive Impairment: Relationship to Cognitive Deficits.”, J Alzheimers Dis, vol. 96, no. 1, pp. 215-227, 2023.
, “Serotonin Degeneration and Amyloid-β Deposition in Mild Cognitive Impairment: Relationship to Cognitive Deficits.”, J Alzheimers Dis, vol. 96, no. 1, pp. 215-227, 2023.
, “Serotonin Degeneration and Amyloid-β Deposition in Mild Cognitive Impairment: Relationship to Cognitive Deficits.”, J Alzheimers Dis, vol. 96, no. 1, pp. 215-227, 2023.
, “Soluble TREM2, Alzheimer's Disease Pathology, and Risk for Progression of Cerebral Small Vessel Disease: A Longitudinal Study.”, J Alzheimers Dis, vol. 92, no. 1, pp. 311-322, 2023.
, “Understanding the Involvement of microRNAs in Mitochondrial Dysfunction and Their Role as Potential Biomarkers and Therapeutic Targets in Parkinson's Disease.”, J Alzheimers Dis, vol. 94, no. s1, pp. S187-S202, 2023.
, “Unlocking Modifiable Risk Factors for Alzheimer's Disease: Does the Oral Microbiome Hold Some of the Keys?”, J Alzheimers Dis, vol. 92, no. 4, pp. 1111-1129, 2023.
,